// App-Quantinova.ai

3539 : The Reciprocal t(9;22) p96ABL/BCR fusion Protein Eenhances the Transformation Potential of BCR/ABL and Increases Therapy Resistance in Models of Ph+ Acute Lymphatic Leukemia

Researchers

Presenter

  • Afsar Mian

Principal Investigators

  • Anna Metodieva

  • Claudia Oancea

  • Hubert Serve

  • Heike Pfeifer

  • Oliver G. Ottmann

  • Martin Ruthardt

Medical Centers

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Nucleoside diphosphate kinase A

  • Ph chromosome

Drug/Treatment

  • Nilotinib

  • dasatinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved